Rivoglitazone: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Rivoglitazone": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +)) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 28: | Line 28: | ||
{{CMG}} | {{CMG}} | ||
'''Rivoglitazone''' ([[International Nonproprietary Name|INN]]) is a [[thiazolidinedione]] undergoing research for use in the treatment of [[type 2 diabetes]].<ref name="pmid17458185">{{cite journal |author=Schimke K, Davis TM |title=Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes |journal=Curr Opin Investig Drugs |volume=8 |issue=4 |pages=338–44 |year=2007 |pmid=17458185 |doi=}}</ref> | '''Rivoglitazone''' ([[International Nonproprietary Name|INN]]) is a [[thiazolidinedione]] undergoing research for use in the treatment of [[type 2 diabetes]].<ref name="pmid17458185">{{cite journal |author=Schimke K, Davis TM |title=Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes |journal=Curr Opin Investig Drugs |volume=8 |issue=4 |pages=338–44 |year=2007 |pmid=17458185 |doi=}}</ref> | ||
| Line 35: | Line 35: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
{{-}} | {{-}} | ||
{{Oral hypoglycemics}} | {{Oral hypoglycemics}} | ||
Latest revision as of 14:28, 6 September 2012
| File:Rivoglitazone.svg | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C20H19N3O4S |
| Molar mass | 397.448 g/mol |
| 3D model (JSmol) | |
| |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes.[1]
It is being developed by Daiichi Sankyo Co.
References
Categories:
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Thiazolidinediones